MCID: ACT073
MIFTS: 61

Acute Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia 38 12 29 55 15 73
Acute Undifferentiated Leukemia 73
Undifferentiated Leukemia 73
Stem Cell Leukaemia 12
Stem Cell Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12603
ICD10 33 C95.0 C95.00
ICD9CM 35 208.0
NCIt 50 C9300
SNOMED-CT 68 24072005 91855006

Summaries for Acute Leukemia

Disease Ontology : 12 A leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity. These lymphocytes (acute lymphocytic leukemia [ALL]) or myeloid cells (acute myelocytic leukemia [AML]) proliferate abnormally, replacing normal marrow tissue and hematopoietic cells and inducing anemia, thrombocytopenia, and granulocytopenia.

MalaCards based summary : Acute Leukemia, also known as acute undifferentiated leukemia, is related to chronic eosinophilic leukemia and leukemia, acute lymphoblastic. An important gene associated with Acute Leukemia is BAALC (BAALC, MAP3K1 And KLF4 Binding), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Busulfex and Clolar have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Acute Leukemia Chronic Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
# Related Disease Score Top Affiliating Genes
1 chronic eosinophilic leukemia 32.4 FLT3 KIT WT1
2 leukemia, acute lymphoblastic 32.3 AFF1 ANPEP DNTT ETV6 FLT3 KMT2A
3 megakaryocytic leukemia 32.3 JAK2 MPO RUNX1
4 acute promyelocytic leukemia 32.3 ANPEP CD34 CEBPA CSF3 FLT3 MPO
5 childhood leukemia 32.3 ETV6 KMT2A MLLT3 MTHFR RUNX1
6 acute lymphocytic leukemia 32.2 CSF3 ETV6 GSTM1 MTHFR RUNX1
7 leukemia 32.2 BAALC CEBPA CREBBP ETV6 FLT3 JAK2
8 lymphoblastic lymphoma 32.1 DNTT KMT2A MPO
9 leukemia, acute myeloid 31.6 AFF1 ANPEP BAALC CD34 CEBPA CSF3
10 myelodysplastic syndrome 30.8 ANPEP CD34 CEBPA CREBBP CSF3 DNTT
11 lymphocytic leukemia 30.7 DNTT ETV6 KMT2A RUNX1
12 myeloid leukemia 30.5 CEBPA CREBBP ETV6 FLT3 JAK2 KIT
13 lymphoid leukemia 30.1 ETV6 FLT3 JAK2 KMT2A
14 chronic myelomonocytic leukemia 30.0 ETV6 FLT3 JAK2 KIT RUNX1
15 myeloma, multiple 29.9 CD34 CSF3 JAK2 KIT
16 myeloid sarcoma 29.8 ANPEP DNTT FLT3 KIT KMT2A MPO
17 lymphoma, non-hodgkin, familial 29.8 CD34 CSF3 DNTT JAK2
18 8p11 myeloproliferative syndrome 29.7 FLT3 KIT RUNX1
19 cytogenetically normal acute myeloid leukemia 29.6 CEBPA FLT3 KMT2A WT1
20 acute erythroid leukemia 29.6 CEBPA JAK2
21 aplastic anemia 29.5 CD34 CSF3 FLT3 GSTM1
22 myelofibrosis 29.4 CD34 CSF3 FLT3 JAK2 KIT
23 gastrointestinal stromal tumor 29.4 CD34 FLT3 KIT MTHFR
24 leukemia, chronic myeloid 29.0 CD34 CSF3 DNTT ETV6 FLT3 JAK2
25 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 28.9 CREBBP DNTT ETV6 FLT3 KIT KMT2A
26 precursor t-cell acute lymphoblastic leukemia 28.7 ANPEP CD34 DNTT ETV6 FLT3 KMT2A
27 acute leukemia of ambiguous lineage 12.4
28 chromosome 8p11 myeloproliferative syndrome 11.8
29 invasive aspergillosis 11.3
30 chronic leukemia 11.3
31 myelodysplastic myeloproliferative cancer 11.0
32 severe congenital neutropenia 11.0
33 myeloproliferative neoplasm 11.0
34 mthfr gene variant 11.0
35 hematopoietic stem cell transplantation 10.5
36 chromophobe renal cell carcinoma 10.4
37 renal oncocytoma 10.4
38 lymphoma 10.3
39 acute myeloid leukemia with t(9;11)(p22;q23) 10.3 KMT2A MLLT3
40 subacute myeloid leukemia 10.3 FLT3 JAK2
41 ring chromosome 21 10.3 ETV6 KMT2A
42 acute myeloblastic leukemia with maturation 10.3 FLT3 KIT
43 testicular gonadoblastoma 10.3 KIT WT1
44 b-cell childhood acute lymphoblastic leukemia 10.3 ETV6 RUNX1
45 acute myeloid leukemia with minimal differentiation 10.3 FLT3 MPO
46 nondisjunction 10.2 KIT MTHFR
47 blood coagulation disease 10.2 CSF3 JAK2 MTHFR
48 congenital mesoblastic nephroma 10.2 ETV6 KIT WT1
49 graft-versus-host disease 10.2
50 malignant mesenchymoma 10.2 ETV6 KIT WT1

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):


Deficiency Anemia Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:



Diseases related to Acute Leukemia

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.32 FLT3
2 Decreased viability GR00221-A-1 10.32 FLT3 KIT
3 Decreased viability GR00221-A-2 10.32 JAK2
4 Decreased viability GR00221-A-4 10.32 FLT3
5 Decreased viability GR00301-A 10.32 KIT
6 Decreased viability GR00381-A-1 10.32 AFF1 GSTM1 WT1
7 Decreased viability GR00402-S-2 10.32 AFF1 ANPEP BAALC CD34 CEBPA CREBBP
8 no effect GR00402-S-1 9.96 AFF1 ANPEP BAALC CD34 CEBPA CREBBP
9 Reduced mammosphere formation GR00396-S 9.17 CD34 CEBPA CSF3 ETV6 GSTM1 KMT2A

MGI Mouse Phenotypes related to Acute Leukemia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 AFF1 ANPEP CD34 CEBPA CREBBP CSF3
2 immune system MP:0005387 10.34 AFF1 ANPEP CD34 CEBPA CREBBP CSF3
3 homeostasis/metabolism MP:0005376 10.3 CD34 CEBPA CREBBP DNTT ETV6 FLT3
4 cardiovascular system MP:0005385 10.28 ANPEP CEBPA CREBBP DNTT ETV6 KIT
5 growth/size/body region MP:0005378 10.27 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
6 endocrine/exocrine gland MP:0005379 10.21 AFF1 ANPEP CEBPA CREBBP ETV6 FLT3
7 integument MP:0010771 10.14 ANPEP CD34 CEBPA CREBBP CSF3 ETV6
8 embryo MP:0005380 10.13 CREBBP ETV6 JAK2 KIT KMT2A MLLT3
9 mortality/aging MP:0010768 10.13 AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
10 liver/biliary system MP:0005370 9.97 CEBPA CREBBP JAK2 KIT KMT2A MTHFR
11 neoplasm MP:0002006 9.9 CD34 CEBPA CREBBP ETV6 FLT3 JAK2
12 muscle MP:0005369 9.8 CEBPA CREBBP KIT KMT2A MPO STMN1
13 no phenotypic analysis MP:0003012 9.65 AFF1 CEBPA ETV6 FLT3 KIT KMT2A
14 normal MP:0002873 9.32 CEBPA CREBBP DNTT ETV6 JAK2 KIT

Drugs & Therapeutics for Acute Leukemia

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
2
Clolar 18 49 CLOFARABINE Genzyme December, 2004
3
Marqibo 18 49 VINCRISTINE SULFATE Talon Therapeutics August 2012

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 367)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Not Applicable 1327-53-3 518740
2
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
5
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 32326 21704
6
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
7
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
8
Fludarabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 75607-67-9, 21679-14-1 30751
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
10
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
11
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 171228-49-2 147912
12
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
13 Antiparasitic Agents Phase 4,Phase 3,Phase 2
14 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
15 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
17 Antiprotozoal Agents Phase 4,Phase 3,Phase 2
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Liposomal amphotericin B Phase 4,Phase 3,Phase 2
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
22 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
23 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
25 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
26 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Thymoglobulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
32 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Echinocandins Phase 4,Phase 2,Phase 1
39
Voriconazole Approved, Investigational Phase 3 137234-62-9 71616
40
Oprelvekin Approved, Investigational Phase 2, Phase 3 145941-26-0
41
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 320-67-2 9444
42
Decitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 2353-33-5 451668
43
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 123318-82-1 119182
44
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
45
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
46
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
47
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
48
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
49
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
50
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 504)
# Name Status NCT ID Phase Drugs
1 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
2 PROPHYSOME: Pilot Study on Safety of a Weekly Administration of 10mg/kg of AmBisome® in Antifungal Prophylaxis Treatment of Allogeneic Stem-cell Transplantation and Acute Leukaemia Completed NCT00362544 Phase 4 Ambisome
3 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
4 Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Completed NCT00504764 Phase 4 Arsenic Trioxide;ATRA
5 Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Not yet recruiting NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
6 A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Not yet recruiting NCT03190733 Phase 4 ATG
7 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
8 ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
9 Antifungal Prophylaxis in Pediatric Acute Leukemia Unknown status NCT00624143 Phase 3 ORAL VORICONAZOLE and IV Amphotericin B
10 A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission Unknown status NCT01067300 Phase 3
11 Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Unknown status NCT02241031 Phase 2, Phase 3 thrombopoietin (TPO) and interleukin-11
12 Transfusion Strategy in Hematological Intensive Care Unit Unknown status NCT02461264 Phase 3 Single red blood packed cells Transfusion;Two packed red blood cells Transfusion
13 MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT Unknown status NCT02673008 Phase 2, Phase 3
14 Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome Unknown status NCT01809392 Phase 2, Phase 3 decitabine
15 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
16 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
17 Clove In The Treatment Of Relapsed Or Resistant Acute Leukemia In Children Completed NCT01385891 Phase 2, Phase 3 Clofarabine VP 16 ciclophospahamide
18 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed NCT01371656 Phase 3 levofloxacin
19 Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
20 Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission Completed NCT00002534 Phase 3 cyclophosphamide;cytarabine;methylprednisolone;thiotepa
21 Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation Completed NCT01020175 Phase 3
22 Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen Completed NCT00774280 Phase 3 BuCy vs BuFlu
23 Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia Completed NCT00002700 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;prednisone;therapeutic hydrocortisone;vincristine sulfate
24 Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 Completed NCT00931138 Phase 3 chemotherapy (Aracytine + Daunorubicin);chemotherapy (Aracytine + Daunorubicin);chemotherapy (Aracytine + Daunorubicin)
25 A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old Completed NCT00927498 Phase 3 conventional chemotherapy (AraC + Daunorubicin),;Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
26 Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) Completed NCT00880243 Phase 3 GM-CSF
27 A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients Completed NCT00163722 Phase 3
28 Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Completed NCT00093990 Phase 3 Tipifarnib;Zarnestra; R115777
29 Timed-Sequential Induction in CBF-AML Completed NCT00428558 Phase 3 Chemotherapy (DAUNORUBICINE-CYTARABINE);Chemotherapy (DAUNORUBICINE-CYTARABINE)
30 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
31 Prevention of Left Ventricular Dysfunction During Chemotherapy Completed NCT01110824 Phase 3 Enalapril and carvedilol
32 Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT Recruiting NCT03596892 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY)
33 Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Recruiting NCT03799224 Phase 2, Phase 3 Decitabine;mBU/CY and ATG;mBU/CY
34 Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Recruiting NCT03793517 Phase 2, Phase 3 Decitabine;mBU/CY and ATG;mBU/CY
35 Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Recruiting NCT00914628 Phase 3
36 HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT Recruiting NCT03662087 Phase 2, Phase 3
37 Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) Recruiting NCT03016130 Phase 3
38 Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301) Recruiting NCT02345850 Phase 3 Cyclophosphamide;Tacrolimus;Methotrexate
39 Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Recruiting NCT03595800 Phase 3
40 Eltrombopag Used in Thrombocytopenia After Comsolidation Therapy in AML Recruiting NCT03701217 Phase 2, Phase 3 Eltrombopag
41 Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients Recruiting NCT02730299 Phase 3 NiCord®
42 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
43 Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients Active, not recruiting NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
44 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Active, not recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
45 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
46 Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome Active, not recruiting NCT01243476 Phase 3 Lenalidomide
47 Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) Terminated NCT00038805 Phase 2, Phase 3 Mylotarg
48 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
49 Stem Cell Transplantation for Hematological Malignancies Terminated NCT00176839 Phase 2, Phase 3 Busulfan;Cyclophosphamide;Melphalan;G-CSF;ATG
50 Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated NCT02785900 Phase 3 33A;placebo;azacitidine;decitabine

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Acute Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Acute Leukemia:
Promostem�, mesenchymal stem cells for treatment of graft-versus-host disease

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

# Genetic test Affiliating Genes
1 Acute Leukemia 29

Anatomical Context for Acute Leukemia

MalaCards organs/tissues related to Acute Leukemia:

41
Myeloid, Bone, Bone Marrow, T Cells, B Cells, Nk Cells, Liver

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 2367)
# Title Authors Year
1
Peripheral blood flow cytometry for the diagnosis of pediatric acute leukemia: Highly reliable with rare exceptions. ( 30255571 )
2019
2
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. ( 30528805 )
2019
3
Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression. ( 29951132 )
2018
4
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. ( 29330396 )
2018
5
Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: a Controlled, Cross-Sectional Study. ( 29951178 )
2018
6
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
7
Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. ( 29953464 )
2018
8
Maternal Exposure to Pesticides, Paternal Occupation in the Army/Police Force, and CYP2D6*4 Polymorphism in the Etiology of Childhood Acute Leukemia. ( 29432309 )
2018
9
Re-induction chemotherapy using FLAG-mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates. ( 29951735 )
2018
10
Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia. ( 29947237 )
2018
11
Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia. ( 29696242 )
2018
12
Relatively favorable prognosis for MLL-rearranged childhood acute leukemia with reciprocal translocations. ( 29943896 )
2018
13
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )
2018
14
Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia. ( 29423036 )
2018
15
Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study. ( 29956075 )
2018
16
Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma. ( 29416774 )
2018
17
The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. ( 29899571 )
2018
18
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction. ( 29399859 )
2018
19
Clinical significance of the TNF-I+ receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia. ( 29861382 )
2018
20
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. ( 29449681 )
2018
21
Congestive heart failure among children with acute leukemia: a population-based matched cohort study. ( 29966479 )
2018
22
Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. ( 29981272 )
2018
23
VEGF signaling in acute leukemia: mitochondrial connections. ( 29854867 )
2018
24
Clinicohematological Profile of Febrile Neutropenia in Childhood Acute Leukemia and Utility of Serum Procalcitonin Levels in Neutropenic Patients. ( 29910543 )
2018
25
Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study. ( 29413281 )
2018
26
Stodtmeister Cells (Polymorphs with Pelger-HuA<t Anomaly) Showing &amp;quot;Faggots&amp;quot; in Mixed Phenotypic Acute Leukemia (T/Myeloid). ( 29398816 )
2018
27
Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia. ( 29346763 )
2018
28
Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients. ( 29310512 )
2018
29
Novel biallelic ATM mutations coexist with a mosaic form of triple X syndrome in an 11-year-old girl at remission after T cell acute leukemia. ( 29492593 )
2018
30
Oral health status in adult patients with newly diagnosed acute leukemia. ( 28536781 )
2018
31
Mometasone furoate inhibits growth of acute leukemia cells in childhood by regulating PI3K signaling pathway. ( 29421985 )
2018
32
Clinical and Genomic Characterization of Recurrent Enterococcal Bloodstream Infection in Patients With Acute Leukemia. ( 29977964 )
2018
33
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients with intensive chemotherapy. ( 29880612 )
2018
34
Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. ( 29928170 )
2018
35
Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda. ( 29307444 )
2018
36
Single Dose Daily Fractionated Is Not Inferior To Twice A Day Fractionated Total Body Irradiation Prior To Allogeneic Stem Cell Transplantation For Acute Leukemia: A Useful Practice Simplification Resulting From The Sarasin Study. ( 29928948 )
2018
37
Diagnostic Dilemma in Ambiguous Lineage Acute Leukemia: A Case Report. ( 29398827 )
2018
38
Acute bilateral retina hemorrhages beneath internal limiting membrane: An unusual ophthalmological case report of acute leukemia during complete clinical remission. ( 29443727 )
2018
39
Targeting the bone marrow microenvironment in acute leukemia. ( 29431560 )
2018
40
Hematopoietic cell transplantation for myeloid/NK cell precursor acute leukemia in second remission. ( 29881556 )
2018
41
Clinical Outcome, Healthcare Cost and Length of Hospital Stay Among Patients With Bloodstream Infections and Acute Leukemia in a Cancer Center in Eastern India. ( 29909820 )
2018
42
Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia. ( 29969046 )
2018
43
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients. ( 29334284 )
2018
44
Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. ( 30036572 )
2018
45
Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges. ( 30047795 )
2018
46
NUT midline carcinoma with leukemic presentation mimicking CD34-positive acute leukemia. ( 30049733 )
2018
47
Targeted therapy for fusion-driven high-risk acute leukemia. ( 30049809 )
2018
48
Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. ( 30066039 )
2018
49
Trisenox induces cytotoxicity through phosphorylation of mitogen-activated protein kinase molecules in acute leukemia cells. ( 30091188 )
2018
50
Clinical outcome, healthcare cost and length of hospital stay among patients with bloodstream infections and acute leukemia in a cancer center in Eastern india - CORRIGENDUM. ( 30091693 )
2018

Variations for Acute Leukemia

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Pathways for Acute Leukemia

GO Terms for Acute Leukemia

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.85 CEBPA CREBBP KMT2A MLLT3 RUNX1 WT1
2 transcription by RNA polymerase II GO:0006366 9.8 CEBPA ETV6 KMT2A MLLT3 RUNX1 WT1
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.72 CSF3 JAK2 KIT
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 FLT3 JAK2 KIT
5 cytokine-mediated signaling pathway GO:0019221 9.65 CEBPA CSF3 FLT3 JAK2 KIT
6 embryonic hemopoiesis GO:0035162 9.54 KIT KMT2A
7 regulation of myeloid cell differentiation GO:0045637 9.51 CREBBP RUNX1
8 granulocyte differentiation GO:0030851 9.49 CEBPA CSF3
9 hemopoiesis GO:0030097 9.46 CD34 FLT3 KIT RUNX1
10 myeloid progenitor cell differentiation GO:0002318 9.4 FLT3 KIT
11 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.26 CSF3 FLT3 JAK2 KIT
12 hematopoietic stem cell proliferation GO:0071425 8.8 CD34 ETV6 RUNX1
13 regulation of transcription, DNA-templated GO:0006355 10.03 AFF1 CEBPA CREBBP ETV6 KMT2A MLLT3
14 cell differentiation GO:0030154 10 ANPEP ETV6 FLT3 JAK2 KIT STMN1
15 positive regulation of transcription by RNA polymerase II GO:0045944 10 CEBPA CREBBP CSF3 ETV6 KMT2A RUNX1

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 FLT3 JAK2 KIT
2 transcription regulatory region DNA binding GO:0044212 9.26 CEBPA KMT2A RUNX1 WT1
3 DNA-binding transcription factor activity GO:0003700 9.17 AFF1 CEBPA CREBBP ETV6 KMT2A RUNX1
4 lysine-acetylated histone binding GO:0070577 9.16 KMT2A MLLT3

Sources for Acute Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....